Ailish Finnerty

Ailish specialises in corporate tax with a particular focus on tax planning for international clients doing business in and through Ireland.

Ailish acts for a broad range of international clients including financial institutions, multi-national corporations, private equity houses and hedge funds as well as growth and emerging companies, particularly in the life sciences and technology sectors. She has advised numerous US clients on establishing operations in Ireland and has extensive experience in intangibles planning in and through Ireland. Ailish advises on the tax aspects of a wide variety of transactions, including leasing transactions, mergers and acquisitions, disposals, reorganisations and corporate restructurings, inward investment projects, securitisations and all forms of structured financing.

Relevant Experience

• Advising a number of publicly traded US companies operating in the life science and technology sectors on the migration of their intellectual property portfolios to Ireland including from CV/BV structures and offshore jurisdictions
• Advising a consortium of European banks on their joint business venture for the commercialisation and development of the ‘we.trade’ platform
• Advising Tyco International on its migration from Switzerland to Ireland in 2014
• Advising ON Semiconductor on its acquisition of SensL Technologies
• Advising Irish Stock Exchange plc on its acquisition by Euronext NV
• Advising Adesto Technologies on the acquisition of the hived-out S3 ASIC Semiconductor business of Silicon Software & Systems Limited
• Advising Allergan plc on its proposed $150 billion merger with Pfizer Inc.
• Advising CRH plc on its acquisition of assets from Lafarge and Holcim for €6.5 billion
• Advising Actavis plc on its $66 billion White Knight acquisition of Allergan, including an $8.4 billion simultaneous ordinary and convertible share offering
• Advising Allergan Plc on its $40 billion disposal of its generics business to Teva Pharmaceuticals and its $2 billion acquisition of Kythera Biopharmaceuticals, Inc.